Trial · NCT03482440
Angiotensin II and Chronic Inflammation in Persistent Microvascular Dysfunction Following Preeclampsia
NCT03482440, Early phase 1, Completed, University of Iowa; results first posted 2025-06-03
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Angiotensin II and Chronic Inflammation in Persistent Microvascular Dysfunction Following Preeclampsia. Trials, record NCT03482440. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03482440
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Angiotensin II and Chronic Inflammation in Persistent Microvascular Dysfunction Following Preeclampsia
- NCT number
- NCT03482440
- Status
- Completed
- Phases
- Early phase 1
- Enrollment
- 24 participants, actual
- Lead sponsor
- University of Iowa
- Conditions
- Preeclampsia
- Interventions
- Salsalate Oral Tablet, Placebo Oral Tablet
- First posted
- 2018-03-29
- Last updated
- 2025-06-03
- Results first posted
- 2025-06-03
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Microvascular Endothelial Function (Cutaneous Conductance, %Maximum) | immediately following the 4 days or oral treatment (salsalate or placebo) | Endothelium-dependent vasodilation assessed as cutaneous conductance response (cutaneous conductance = local red blood cell flux/mean arterial pressure; %maximum) to exogenous acetylcholine delivered via intradermal microdialysis. |
| Secondary | Peripheral Blood Mononuclear Cell Inflammatory Response to Ang II | at the completion of 4 days of oral (placebo or salsalate) treatment | inflammatory cytokine (TNFalpha) release by peripheral blood mononuclear cells isolated from fresh whole blood collected via venipuncture and stimulated with angiotensin II ex vivo. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Microvascular Endothelial Function (Cutaneous Conductance, %Maximum) | immediately following the 4 days or oral treatment (salsalate or placebo) | % of maximal cutaneous conductance | MEAN | |
| SECONDARY | Peripheral Blood Mononuclear Cell Inflammatory Response to Ang II | at the completion of 4 days of oral (placebo or salsalate) treatment | ng/ml | MEAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Microvascular Endothelial Function (Cutaneous Conductance, %Maximum) | Oral Salsalate | 95 | Standard Deviation 6 | % of maximal cutaneous conductance | |
| Microvascular Endothelial Function (Cutaneous Conductance, %Maximum) | Oral Placebo | 77 | Standard Deviation 8 | % of maximal cutaneous conductance | |
| Peripheral Blood Mononuclear Cell Inflammatory Response to Ang II | Oral Salsalate | 2.37 | Standard Deviation 1.28 | ng/ml | |
| Peripheral Blood Mononuclear Cell Inflammatory Response to Ang II | Oral Placebo | 2.77 | Standard Deviation 1.01 | ng/ml |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Placebo Then Salsalate | 13 | |
| Overall Study | STARTED | Salsalate Then Placebo | 10 | |
| Overall Study | COMPLETED | Placebo Then Salsalate | 13 | |
| Overall Study | COMPLETED | Salsalate Then Placebo | 10 | |
| Overall Study | NOT COMPLETED | Placebo Then Salsalate | 0 | |
| Overall Study | NOT COMPLETED | Salsalate Then Placebo | 0 |
Source ClinicalTrials.gov
Adverse events2
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | tennitis while on salsalate | Ear and labyrinth disorders | Placebo | 0 | 23 | 0 |
| other | tennitis while on salsalate | Ear and labyrinth disorders | Salsalate | 2 | 23 | 2 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Placebo | 0 | 23 |
| Total, all-cause mortality | Salsalate | 0 | 23 |
| Total, other adverse events | Placebo | 0 | 23 |
| Total, other adverse events | Salsalate | 2 | 23 |
| Total, serious adverse events | Placebo | 0 | 23 |
| Total, serious adverse events | Salsalate | 0 | 23 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Salsalate vs Placebo: deaths from any cause | Trial comparisons |
| Salsalate vs Placebo: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03482440
GET https://conductscience.org/api/trials/v1/NCT03482440/registered